Novel Expression Patterns of PI3K/Akt/mTOR Signaling Pathway Components in Colorectal Cancer (original) (raw)

Abstract

BACKGROUND-The PI3K/Akt/mTOR pathway plays a critical role in the growth and progression of colorectal cancer (CRC). The purpose of our study was twofold: 1) to determine the expression levels of several key components of this pathway including p85α, Akt1, Akt2, p-mTOR Ser2448 and p-p70S6K Thr389 in CRCs, and 2) to correlate the expression of these proteins with cancer stage and location (left-vs. right-sided). STUDY DESIGN-Immunohistochemistry for p85α, Akt1, Akt2, p-mTOR Ser2448 and p-p70S6K Thr389 was performed on normal colon and CRCs from 154 patients. RESULTS-All proteins investigated were significantly overexpressed in CRCs compared to matched normal colonic tissue from the same patient (p<0.0001). The PI3K pathway component proteins were moderately correlated across normal and malignant colon tissues; correlations tended to be stronger in normal tissues as compared to the same correlations in cancers. Expression levels of p85α were significantly higher in Stage IV cancers than in Stage I-III cancers (p = 0.0005); interestingly, p85α expression was also significantly increased in the adjacent normal colonic mucosa of patients with Stage IV CRC compared with earlier stages (p=0.003). Finally, expression of Akt1, Akt2, and p-p70S6K Thr389 was higher in left-sided CRCs compared with CRCs in the right colon (p = 0.007, p = 0.0008, and p = 0.04, respectively). CONCLUSIONS-The PI3K/Akt/mTOR pathway components, p85α, Akt1, Akt2, p-mTOR Ser2448 and p-p70S6K Thr389 , are highly overexpressed in CRCs thus providing the rationale

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (37)

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249. [PubMed: 19474385]
  2. Griffin MR, Bergstralh EJ, Coffey RJ, et al. Predictors of survival after curative resection of carcinoma of the colon and rectum. Cancer 1987;60:2318-2324. [PubMed: 3440238]
  3. Kobayashi M, Nagata S, Iwasaki T, et al. Dedifferentiation of adenocarcinomas by activation of phosphatidylinositol 3-kinase. Proc Natl Acad Sci U S A 1999;96:4874-4879. [PubMed: 10220386]
  4. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655-1657. [PubMed: 12040186]
  5. Philp AJ, Campbell IG, Leet C, et al. The phosphatidylinositol 3'-kinase p85α gene is an oncogene in human ovarian and colon tumors. Cancer Res 2001;61:7426-7429. [PubMed: 11606375]
  6. Roy HK, Olusola BF, Clemens DL, et al. AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 2002;23:201-205. [PubMed: 11756242]
  7. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006;441:424-430. [PubMed: 16724053]
  8. Brugge J, Hung MC, Mills GB. A new mutational AKTivation in the PI3K pathway. Cancer Cell 2007;12:104-107. [PubMed: 17692802]
  9. Rychahou PG, Jackson LN, Silva SR, et al. Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma. Ann Surg 2006;243:833- 842. discussion 843-834. [PubMed: 16772787]
  10. Khaleghpour K, Li Y, Banville D, et al. Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma. Carcinogenesis 2004;25:241-248. [PubMed: 14578160]
  11. Itoh N, Semba S, Ito M, et al. Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer 2002;94:3127-3134. [PubMed: 12115344]
  12. Rychahou PG, Murillo CA, Evers BM. Targeted RNA interference of PI3K pathway components sensitizes colon cancer cells to TNF-related apoptosis-inducing ligand (TRAIL). Surgery 2005;138:391-397. [PubMed: 16153452]
  13. Rychahou PG, Kang J, Gulhati P, et al. Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proc Natl Acad Sci U S A 2008;105:20315-20320. [PubMed: 19075230]
  14. Sheng H, Shao J, Townsend CM Jr, Evers BM. Phosphatidylinositol 3-kinase mediates proliferative signals in intestinal epithelial cells. Gut 2003;52:1472-1478. [PubMed: 12970141]
  15. Wang Q, Li N, Wang X, et al. Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3'-kinase inhibition in the KM20 human colon cancer cell line. Clin Cancer Res 2002;8:1940-1947. [PubMed: 12060639]
  16. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22. [PubMed: 17613433]
  17. Chiang GG, Abraham RT. Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem 2005;280:25485-25490. [PubMed: 15899889]
  18. Gulhati P, Cai Q, Li J, et al. Targeted inhibition of mTOR signaling inhibits tumorigenesis of colorectal cancer. Clin Cancer Res. 2009 In press.
  19. Iacopetta B. Are there two sides to colorectal cancer? Int J Cancer 2002;101:403-408. [PubMed: 12216066]
  20. Altomare DA, Tanno S, De Rienzo A, et al. Frequent activation of AKT2 kinase in human pancreatic carcinomas. J Cell Biochem 2002;87:470-476. [PubMed: 14735903]
  21. Yuan ZQ, Sun M, Feldman RI, et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 2000;19:2324-2330. [PubMed: 10822383]
  22. Han Z, Wu K, Shen H, et al. Akt1/protein kinase B alpha is involved in gastric cancer progression and cell proliferation. Dig Dis Sci 2008;53:1801-1810. [PubMed: 18379876]
  23. Carpten JD, Faber AL, Horn C, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007;448:439-444. [PubMed: 17611497]
  24. Bleeker FE, Felicioni L, Buttitta F, et al. AKT1(E17K) in human solid tumours. Oncogene. 2008
  25. Wan X, Harkavy B, Shen N, et al. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007;26:1932-1940. [PubMed: 17001314]
  26. Manning BD. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 2004;167:399-403. [PubMed: 15533996]
  27. Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008;118:3065- 3074. [PubMed: 18725988]
  28. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767. [PubMed: 2188735]
  29. Giovannucci E, Ogino S. DNA methylation, field effects, and colorectal cancer. J Natl Cancer Inst 2005;97:1317-1319. [PubMed: 16174847]
  30. Distler P, Holt PR. Are right-and left-sided colon neoplasms distinct tumors? Dig Dis 1997;15:302- 311. [PubMed: 9359018]
  31. Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med 1990;113:779-788. [PubMed: 2240880]
  32. Wistuba II, Behrens C, Albores-Saavedra J, et al. Distinct K-ras mutation pattern characterizes signet ring cell colorectal carcinoma. Clin Cancer Res 2003;9:3615-3619. [PubMed: 14506148]
  33. Edkins S, O'Meara S, Parker A, et al. Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther 2006;5:928-932. [PubMed: 16969076]
  34. Gupta S, Ramjaun AR, Haiko P, et al. Binding of ras to phosphoinositide 3-kinase p110α is required for ras-driven tumorigenesis in mice. Cell 2007;129:957-968. [PubMed: 17540175]
  35. Lim KH, Counter CM. Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/ AKT pathway during tumor maintenance. Cancer Cell 2005;8:381-392. [PubMed: 16286246]
  36. Junttila MR, Evan GI. p53--a Jack of all trades but master of none. Nat Rev Cancer 2009;9:821-829. [PubMed: 19776747]
  37. Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A 2005;102:8204-8209. [PubMed: 15928081]